Practical implementation of the 2021 European Society of Cardiology Heart Failure Guidelines – focusing on the Guideline-directed Medical Therapy for Heart Failure with Reduced Ejection Fraction
Gottsegen György Országos Kardiovaszkuláris Intézet,
Felnőtt Kardiológiai Osztály, Budapest
Levelezési cím: Dr. Muk Balázs, Gottsegen György Országos Kardiovaszkuláris Intézet, Felnőtt Kardiológiai Osztály;
1096 Budapest, Haller utca 29. E-mail: email@example.com
Heart failure still unquestionably represents a significant public health problem due to its high incidence and prevalence. Although the life expectancy of patients with heart failure has improved significantly thanks to its effective treatment options currently available, the disease still has a poor prognosis.
According to the 2021 European Society of Cardiology (ESC) Heart Failure Guidelines for heart failure with reduced ejection fraction (HFrEF), the use of angiotensin-receptor neprilysin-inhibitor (ARNi) and sodium glucose cotransporter-2 inhibitors (SGLT2i) dapa-, and empagliflozin has become unquestionable pillars of its treatment.
Based on the results of available clinical data and trials, in terms of the complex drug treatment of HFrEF, the early implementation and optimization of all morbidity-, and mortality-reducing first-line agents is essential to improve the prognosis.
This review summarises the main elements of the modern drug treatment of HFrEF according to the current guidelines and details the most relevant clinical problems of the guideline-directed medical therapy’s optimization based on current evidences and consensus documents in HFrEF.
ISSUE: CARDIOLOGIA HUNGARICA | 2023 | VOLUME 53, ISSUE 4
|Watch the video summary
|watch CH Live interview